Apr 4, 2024
In this episode, host Shikha Jain, MD, speaks
with Aparna Parikh, MD, about cancer and GI
malignancies in the global health space, circulating tumor DNA in
the field of oncology and more.
• Welcome to another exciting episode of Oncology
Overdrive :58
• About Parikh 1:07
• The interview 2:08
• What was your path into medicine, cancer care and GI
oncology? 2:35
• Tell us about what you do in the global health space
and what your thoughts are on colon cancer and GI malignancies in
the global health space. 8:07
• Why are we seeing so many more young people being
diagnosed with colon cancer in the US and internationally?
12:24
• Do you think US lifestyle and Western diets compared
to the rest of the world have contributed to the rise of early
colon cancer diagnoses? 15:04
• How can physicians talk about lifestyle, diet and
environmental/social determinants of health that impact a cancer
diagnosis? 17:52
• Can you provide a brief overview of what is
circulating tumor DNA (ctDNA) and liquid biopsy, and how are we
using it in this space? 19:44
• Jain and Parikh on ctDNA as an innovation can be
transformative in the field of GI oncology.
24:06
• What are your predictions for GI oncology in the
next ten to twenty years? 26:06
• If someone could only listen to the last few minutes
of this episode, what would you want them to take away?
28:44
• How to contact Parikh
30:57
• Thanks for listening
31:57
Aparna Parikh, MD, is a GI oncologist at the MGH
Cancer Center where she directs the colorectal research program and
young adults CRC program. She is an associate professor at Harvard
Medical School and an international expert in CRC and liquid
biopsies.
We’d love to hear from you! Send your comments/questions to Dr.
Jain at oncologyoverdrive@healio.com.
Follow Healio on X, formerly known as Twitter, and LinkedIn:
@HemOncToday and
https://www.linkedin.com/company/hemonctoday/.
Follow Dr. Jain on X, formerly known as Twitter:
@ShikhaJainMD. Parikh can be reached via email aparna.parikh@mgh.harvard.edu.
Disclosures: Jain reports no relevant financial
disclosures. Parikh reports equity in C2i Genomics XGenomes Cadex
and Parithera. Advisor/consultant for Abbvie, AZ, Bayer,
Biofidelity, Checkmate Pharmaceuticals, CVS, Delcath, Eli Lilly,
FMI, Guardant, Hookipa, Illumina, Inivata, Mirati, Pfizer, Saga,
Seagen, Taiho, Scare Inc, Science For America, and Value Analytics
Lab. She receives fees from Up to Date. She has received
travel fees from Karkinos Healthcare. She has been on the DSMC for
a Roche study and on Steering Committee for Exilixis. She has
received research funding to the Institution from BMS, Daiichi
Sankyo, Erasca, Genentech, Mirati, Novartis, PMV Pharmaceuticals,
Plexxicon, PureTech, Takeda and Syndax.